3 unknown, 1 completed, 1 suspended, 1 withdrawn. 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Unknown 3, Completed 1, Suspended 1, Withdrawn 1 |
Follow Immunotoxin therapy: new trials by email Literature Review of Immunotoxin therapy trials Research Report on Immunotoxin therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy - Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Unknown | Cambridge Antibody Technology | 50 | 2007-08-01 | 2007-08-14 |
| Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy - Leukemia, Hairy Cell Leukemia | Phase 1 | Unknown | Cambridge Antibody Technology | 40 | 2007-04-01 | 2007-04-18 |
| Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease Immunotoxin therapy, CAT-8015 immunotoxin, Biological therapy - Leukemia | Phase 1 | Unknown | Cambridge Antibody Technology | 50 | 2007-03-01 | 2007-04-17 |
| BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy - Leukemia, Lymphoma | Phase 1 | Completed | MedImmune LLC | 24 | 2005-06-01 | 2010-06-22 |
| BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy - Leukemia, Lymphoma | Phase 1 | Suspended | MedImmune LLC | 95 | 2004-01-01 | 2007-12-28 |
| BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia BL22 immunotoxin, antibody therapy, biological response modifier therapy - Leukemia, Lymphoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2015-04-28 |
Leukemia (6) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Prolymphocytic (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Leukemia, Hairy Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Immunoblastic (1)
Cambridge Antibody Technology (3) · MedImmune LLC (2) · National Cancer Institute (NCI) (1)
United States (6) · Poland (3) · United Kingdom (1)
Robert Kreitman, MD (2) · Alan S. Wayne, MD (1)